drugset / Trial / NCT07726368
Study of ECC4703 With Sulfasalazine and Pitavastatin
Non-randomizedCrossoverOpen-labelTreatment
Summary
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide. ECC4703 is a potential new treatment for non-alcoholic fatty liver disease. The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.
Timeline
- Start
- 2026-08-07
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ECC4703 | Unknown | — | Oral |
| Subject | Pitavastatin | Small molecule | — | Oral |
| Subject | Sulfasalazine | Small molecule | — | Oral |